Digital Content 
NEWS #PharmaBuzz
20 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2025/02/20/3029307/0/en/Apellis-and-Sobi-Announce-EMA-Validation-of-Indication-Extension-Application-for-Aspaveli-pegcetacoplan-for-C3G-and-Primary-IC-MPGN.html
20 Feb 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ema-validates-indication-extension-application-for-aspaveli-for-treatment-of-c3g-and-primary-ic-mpgn-302381200.html
28 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/27/3015964/0/en/Apellis-Receives-Approval-of-SYFOVRE-pegcetacoplan-in-Australia-for-Geographic-Atrophy-GA.html
16 Oct 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/10/16/2963903/0/en/Apellis-Announces-Oral-Presentation-at-American-Society-of-Nephrology-ASN-Kidney-Week-on-Phase-3-VALIANT-Study-of-Pegcetacoplan-in-C3G-and-Primary-IC-MPGN.html
20 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/20/2949536/0/en/Apellis-Receives-Negative-CHMP-Opinion-for-Pegcetacoplan-for-Geographic-Atrophy-GA-in-the-EU-Following-Re-Examination.html
09 Aug 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/sobi-and-apellis-announce-positive-topline-results-from-phase-3-valiant-study-of-pegcetacoplan-in-c3g-and-primary-ic-mpgn-302217847.html
Share 